vTv Therapeutics Inc.
03/14/2024 | Press release | Distributed by Public on 03/14/2024 05:58
Management Change/Compensation - Form 8-K
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On March 12, 2024, Anne Phillips was elected as director of vTv Therapeutics, Inc. (the "Company"), effective and contingent on the filing of the Company's Annual Report on Form 10-K for the year ended December 31, 2023, which occurred on March 13, 2024 (the "2023 Annual Report"). Ms. Phillips was appointed as the Chair of the Compensation Committee of the Board of Directors and a member of the Audit Committee of the Board of Directors.
Ms. Phillips will enter into the Company's standard form of indemnification agreement in connection with her election to the Board, the form of which is attached as Exhibit 10.7 to the Company's Registration Statement on Form S-1, as amended (File No. 333-204951), originally filed with the SEC on June 15, 2015.
Ms. Phillips is an "independent" director as defined within Nasdaq's definition of such term in Section 5605(a) of the Nasdaq rules. Ms. Phillips's appointment as director was not pursuant to any arrangement or understanding with respect to any other person. There are no family relationships between Ms. Phillips and any director or executive officer of the Company, and there are no transactions between Ms. Phillips and the Company that would be required to be reported under Item 404(a) of Regulation S-K.
Consistent with the Current Report on Form 8-K filed on February 23, 2024, John Fry and Howard Weiner resigned from their director roles effective upon the filing of the 2023 Annual Report.